NewsAnalyst coverage on Xbrane Biopharma

In accordance with the communicated statement in Xbrane’s previous shareholder letter, Xbrane inform that the Xbrane share is being analysed by the international research house Edison, which has issued a full initiating coverage.

Edison is an independent investment research firm based in London, with over 100 analysts that provide services to more than 420 retained corporate and investor clients across the globe.

The initiating coverage can be accessed at:

For further information, please contact:
Martin Åmark
Chief Executive Officer
Tel: +46 (0) 763-093 777